Antitumor activity of monomethoxy poly(ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1557-1564

  Zheng, Lan ^a   Gou, Maling ^b   Zhou, Shengtao ^a   Yi, Tao ^a   Zhong, Qian ^a   Li, Zhengyu ^a   He, Xiang ^a   Chen, Xiancheng ^b   Zhou, Lina ^a   Wei, Yuquan ^b   Qian, Zhiyong ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Cardiotoxicity; Doxorubicin; Micelle; MPEG PCL

Indexed keywords

CD31 ANTIGEN; COPOLYMER; CYCLINE; DOXORUBICIN; MONOMETHOXY POLY(ETHYLENE GLYCOL) POLY(EPSILON CAPROLACTONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG RESPONSE; DRUG UPTAKE; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 79954452646     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1243     Document Type: Article

References (33)

1. Rocconi RP, Straughn JM Jr, Leath CA III, et al: Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist 11: 336-341, 2006.
2. Weiss RB, Sarosy G, Clagett-Carr K, Russo M and Leyland-Jones B: Anthracycline analogs the past, present, and future. Cancer Chemother Pharmacol 18: 185-197, 1986. (Pubitemid 17007730)
3. Young CW and Raymond V: Clinical assessment of the structure-activity relationship of anthracycline s and related synthetic derivatives. Cancer Treat Rep 70: 51-63, 1986. (Pubitemid 16140369)
4. Wadler S and Yang P: Reversal of doxorubicin resistance by hydrophobic, but not hydrophilic, forskolins. Mol Pharmacol 40: 960-964, 1991.
5. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A and Papahadjopoulos D: Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54: 2186-2191, 1994. (Pubitemid 24138693)
6. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C and Martin FJ: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991. (Pubitemid 21916061)
7. Lasic DD, Martin FJ, Gabizon A, Huang SK and Papahadjopoulos D: Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070: 187-192, 1991.
8. Gabizon AA, Barenholz Y and Bialer M: Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10: 703-708, 1993. (Pubitemid 23152316)
9. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J and Lasic DD: Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth® liposomes (doxil®). J Liposome Res 4: 667-687, 1994. (Pubitemid 24130564)
10. Unezaki S, Maruyama K, Ishida O, Suginaka A, Hosoda JI and Iwatsuru M: Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly (ethylene glycol). Int J Pharm 126: 41-48, 1995. (Pubitemid 26015624)
11. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A and Siegal T: Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliver Rev 24: 337-344, 1997. (Pubitemid 27112652)
12. Vaage J, Donovan D, Uster P and Working P: Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 75: 482-486, 1997. (Pubitemid 27085286)
13. Skubitz KM and Skubitz AP: Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 9: 45-50, 1998. (Pubitemid 28088178)
14. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785, 1995.
15. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G and Natanson C: Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 114: 664-666, 1991.
16. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P and Karydas AG and Ithakissios DS: PLGA-mPEG nanoparticles of cisplatin in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79: 123-135, 2002. (Pubitemid 34164166)
17. Chytil P, Etrych T, Konák C, et al: Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J Control Release 115: 26-36, 2006. (Pubitemid 44415075)
18. Mitra A, Coleman T, Borgman M, Nan A, Ghandehari H and Line BL: Polymeric conjugates of mono-and bi-cyclic [alpha] v [beta] 3 binding peptides for tumor targeting. J Control Release 114: 175-183, 2006. (Pubitemid 44291848)
19. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F and Chilkoti A: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98: 335-344, 2006. (Pubitemid 43338213)
20. Gabizon AA: Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7: 243-254, 2001.
21. Konishi M, Tabata Y, Kariya M, et al: In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release 92: 301-313, 2003.
22. Kopeek J, Kopeková P, Minko T and Lu Z: HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50: 61-81, 2000. (Pubitemid 30326689)
23. Lee ES, Na K and Bae YH: Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 103: 405-418, 2005. (Pubitemid 40342538)
24. Nishiyama N, Okazaki S, Cabrai H, et al: Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63: 8977-8983, 2003. (Pubitemid 38064079)
25. Duncan R: The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-360, 2003.
26. Khandare J and Minko T: Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31: 359-397, 2006.
27. Cho Y, Kim Y, Kim I, et al: Tumoral accumulation of long-circulating, self-assembled nanoparticles and its visualization by gamma scintigraphy. Macromol Res 16: 15-20, 2008.
28. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M and Speiser P: Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 69: 199-202, 2006.
29. Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56: 1649-1659, 2004. (Pubitemid 39177694)
30. Hall JB, Dobrovolskaia MA, Patri AK and McNeil SE: Characterization of nanoparticles for therapeutics. Nanomedicine 2: 789-803, 2007.
31. Perego P, Corna E, Cesare M, et al: Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8: 31-37, 2001.
32. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J and Gelperina S: Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Lett 178: 9-19, 2008.
33. Tang N, Du G, Wang N, Liu C, Hang H and Liang W: Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 99: 1004-1015, 2007. (Pubitemid 47232602)